- Home
- OTLK vs PLUR Comparison
OTLK vs PLUR Comparison
Compare OTLK & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- PLUR
- Stock Information
- Founded
- OTLK 2010
- PLUR 2001
- Country
- OTLK United States
- PLUR Israel
- Employees
- OTLK N/A
- PLUR N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OTLK Health Care
- PLUR Health Care
- Exchange
- OTLK Nasdaq
- PLUR Nasdaq
- Market Cap
- OTLK 48.3M
- PLUR 44.7M
- IPO Year
- OTLK 2016
- PLUR N/A
- Fundamental
- Price
- OTLK $1.09
- PLUR $4.75
- Analyst Decision
- OTLK Buy
- PLUR Strong Buy
- Analyst Count
- OTLK 5
- PLUR 1
- Target Price
- OTLK $8.50
- PLUR $12.00
- AVG Volume (30 Days)
- OTLK 8.2M
- PLUR 12.0K
- Earning Date
- OTLK 08-14-2025
- PLUR 11-11-2025
- Dividend Yield
- OTLK N/A
- PLUR N/A
- EPS Growth
- OTLK N/A
- PLUR N/A
- EPS
- OTLK N/A
- PLUR N/A
- Revenue
- OTLK $1,505,322.00
- PLUR $1,034,000.00
- Revenue This Year
- OTLK N/A
- PLUR $395.40
- Revenue Next Year
- OTLK $484.88
- PLUR $186.32
- P/E Ratio
- OTLK N/A
- PLUR N/A
- Revenue Growth
- OTLK N/A
- PLUR 203.23
- 52 Week Low
- OTLK $0.79
- PLUR $3.33
- 52 Week High
- OTLK $7.26
- PLUR $7.13
- Technical
- Relative Strength Index (RSI)
- OTLK 37.49
- PLUR 46.58
- Support Level
- OTLK $1.02
- PLUR $4.33
- Resistance Level
- OTLK $1.19
- PLUR $5.17
- Average True Range (ATR)
- OTLK 0.22
- PLUR 0.28
- MACD
- OTLK -0.04
- PLUR -0.02
- Stochastic Oscillator
- OTLK 11.18
- PLUR 43.56
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.